ReviewCureus2025
Omega-3 Polyunsaturated Fatty Acid Supplementation in Children With Attention-Deficit Hyperactivity Disorder (ADHD).
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Polyunsaturated fatty acid (PUFA) supplementation and ADHD outcomes in children and adolescents: a systematic review and meta-analysis of randomized controlled trials.European child & adolescent psychiatry · 2026Review
- Review
- Vitamin D +Docosahexaenoic acid supplementation: effects on serum markers and symptoms in ADHD children.American journal of translational research · 2026Article
- Oxidative Stress, Antioxidant Cofactor Micronutrients, and Cognitive Outcomes in Childhood Obesity: Mechanisms, Evidence, and Therapeutic Opportunities.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omega-3 polyunsaturated fatty acids (PUFAs) have gained attention as a potential adjunctive treatment for attention-deficit hyperactivity disorder (ADHD) due to their roles in cognitive and neurobiological functions such as attention and focus, impulse control, executive function, working memory and neurotransmitter regulation, as well as brain development, mainly prefrontal cortex. ADHD, characterized by cognitive and behavioral challenges, has limited therapeutic options, which has prompted interest in alternative treatments. This narrative review evaluates six primary studies on omega-3 PUFA supplementation in children with ADHD, identified through a search of the PubMed database using outlined MeSH and text-word terms, and filtered for randomized controlled trials. The outcomes varied across studies, with some reporting significant improvements in cognition and behavior, while others found no omega-3 superiority over placebo. One study identified a potential association between increased erythrocyte omega-3 PUFA levels and improved literacy and attention, while others found that eicosapentaenoic acid and DHA supplementation significantly improved working memory function among children diagnosed with ADHD. Collectively, the studies suggest omega-3 PUFA supplementation as a potentially valuable adjunctive treatment for specific ADHD domains. However, methodological variations, inconsistent outcomes, and sample size limitations necessitate caution in drawing definitive conclusions. Further research with standardized protocols, larger samples, and extended intervention durations is imperative to elucidate the impact of omega-3 PUFA supplementation on ADHD symptoms in pediatric populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.